ClinicalTrials.gg
TerminatedNCT01530256ALD518-010Updated Feb 17, 2021Results posted

Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)

A Phase 1/2 interventional study of ALD518 and ALD518 in Acute GvHD, sponsored by CSL Behring. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-17.

Sponsored by CSL Behring (part of CSL Limited) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The trial was terminated in line with the endpoint committee charter.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further investigation in Part B.

02

Conditions studied

  • Acute GvHD

Keywords

  • allograph
  • steroid refractory
03

In context

Lead sponsor

CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.

Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.

First submitted after CSL Behring became part of CSL Limited.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Glucocorticosteroid acute Grade 2-4
  • Prior therapy at > 1.0mg/kg methylprednisolone or equivalent for minimum of 3 and maximum of 14 days
  • Performance Satus Scale ≥ 50%
  • Adequate laboratory testing at screening

Exclusion criteria

Exclusion Criteria:

  • Subjects having Stage 1 skin acute
  • Subjects with Stage 3 or 4 liver GVHD
  • Prior EBV associated
  • Prior or current or C
  • Prior or active tuberculosis
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    ALD518

    Biological: ALD518

Interventions

  • BiologicalALD518

    160 mg IV q 4 weeks for 4 doses

  • BiologicalALD518

    320 mg IV q 4 weeks for 4 doses

  • BiologicalALD518

    640 mg IV q 4 weeks for 2 doses

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events, Including Infections and Loss of Engraftment

    Time frame: Through Week 24

  2. Number of Participants With Acute GVHD Response at Week 4

    Includes calculation of both complete and partial response. Complete response = functional grade of 0 for the GVHD grading in all evaluable organs. Partial response = improvement by one or more functional grades in one or more organs involved with GVHD symptoms without progression in others, or a very good partial response which is a partial response plus all of the following: (1) skin - active erythematous rash involving less than 25% of body surface, (2) liver - total bilirubin \<2 mg/dL or a 25% reduction from baseline (if \>2 mg/dL), (3) gut - greater than or equal to 75% reduction in daily stool volume.

    Time frame: Week 4

Secondary outcomes

  1. Number of Participants With Relapse of Underlying Malignant Disease

    Time frame: Through Week 24

  2. Number of Participants With Overall Survival

    Time frame: Through Week 24

  3. Change in Patient Reported Outcomes as Measured by the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Questionnaire Score

    The FACT-BMT assesses bone marrow transplant related concerns. The total score is the sum of sub-scale scores for 5 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, and Bone Marrow Transplantation Subscale. Within each domain, a 5-point Likert-type scale (from 0-4) is used to measure the responses for each question. After taking into account reverse scores for questions constructed in a negative form, the subscale score for each domain is calculated by multiplying the sum of the item scores by the number of items in the subscale, then dividing by the number of items answered. The final score for FACT-BMT ranges from 0 to 148. Higher scores indicate better quality of life.

    Time frame: Up to 20 weeks

07

Results

Posted Feb 17, 2021
Limitations and caveats
Formal analyses were not conducted. Profiles of each enrolled subject were produced. Due to a limited number of samples, pharmacokinetics and anti-ALD518 antibodies analyses were not conducted.

Participant flow

Participant flow — Overall Study
MilestoneALD518
Started3
Completed1
Not completed2
Withdrew: Death2

Outcome measures

PrimaryNumber of Participants With Adverse Events, Including Infections and Loss of Engraftment
Time frame:
Through Week 24
Reported as:
Number · participants
Number of Participants With Adverse Events, Including Infections and Loss of Engraftment
participantsALD518
Number of Participants With Adverse Events, Including Infections and Loss of Engraftment3
PrimaryNumber of Participants With Acute GVHD Response at Week 4

Includes calculation of both complete and partial response. Complete response = functional grade of 0 for the GVHD grading in all evaluable organs. Partial response = improvement by one or more functional grades in one or more organs involved with GVHD symptoms without progression in others, or a very good partial response which is a partial response plus all of the following: (1) skin - active erythematous rash involving less than 25% of body surface, (2) liver - total bilirubin \<2 mg/dL or a 25% reduction from baseline (if \>2 mg/dL), (3) gut - greater than or equal to 75% reduction in daily stool volume.

Time frame:
Week 4
Reported as:
Number · participants
Number of Participants With Acute GVHD Response at Week 4
participantsALD518
Number of Participants With Acute GVHD Response at Week 40
SecondaryNumber of Participants With Relapse of Underlying Malignant Disease
Time frame:
Through Week 24
Reported as:
Number · participants
Number of Participants With Relapse of Underlying Malignant Disease
participantsALD518
Number of Participants With Relapse of Underlying Malignant Disease0
SecondaryNumber of Participants With Overall Survival
Time frame:
Through Week 24
Reported as:
Number · participants
Number of Participants With Overall Survival
participantsALD518
Number of Participants With Overall Survival1
SecondaryChange in Patient Reported Outcomes as Measured by the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Questionnaire Score

The FACT-BMT assesses bone marrow transplant related concerns. The total score is the sum of sub-scale scores for 5 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, and Bone Marrow Transplantation Subscale. Within each domain, a 5-point Likert-type scale (from 0-4) is used to measure the responses for each question. After taking into account reverse scores for questions constructed in a negative form, the subscale score for each domain is calculated by multiplying the sum of the item scores by the number of items in the subscale, then dividing by the number of items answered. The final score for FACT-BMT ranges from 0 to 148. Higher scores indicate better quality of life.

Time frame:
Up to 20 weeks
Reported as:
Number · score on a scale
Change in Patient Reported Outcomes as Measured by the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Questionnaire Score
score on a scaleALD518
Participant 1 (Day 0)93
Participant 1 (Week 4)96
Participant 1 (Week 12)102
Participant 1 (Week 20)113
Participant 2 (Day 0)55

Adverse events

Collected over Up to death or termination of study (approximately 139 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ALD5182/3 (66.7%)3/3 (100%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventALD518
Renal failure acuteRenal and urinary disorders2/3
SepsisInfections and infestations1/3
Retinal detachmentEye disorders1/3
SinusitisInfections and infestations1/3
Fungal infectionInfections and infestations1/3
Most frequent other events
Showing 10 of 24
Most frequent other events
EventALD518
Blood bilirubin increasedInvestigations2/3
Activated partial thromboplastin time prolongedInvestigations1/3
DyspnoeaRespiratory, thoracic and mediastinal disorders1/3
Blood creatinine increasedInvestigations1/3
HypotensionVascular disorders1/3
Confusional statePsychiatric disorders1/3
International normalized ratio increasedInvestigations1/3
HyponatraemiaMetabolism and nutrition disorders1/3
Cytomegalovirus viraemiaInfections and infestations1/3
Alanine aminotransferase increasedInvestigations1/3

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)ALD518
<=18 years0
Between 18 and 65 years3
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)ALD518
Female1
Male2
Region of Enrollment
Region of Enrollment(participants)ALD518
United States3
08

Study locations

5 sites
  • City of Hope
    Duarte, California 91010, United States
  • Loyola Medical Center
    Maywood, Illinois 60153, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2012 to primary completion in Mar 2013, 12 months.

Results were first posted in Feb 2021, 7 years 11 months after primary completion. A results delay was requested in Jun 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2012
First posted
Feb 9, 2012
StartActual
Mar 2012
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results delay requested
Jun 23, 2014
Results first posted
Feb 17, 2021
Last update
Feb 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01530256
Lead sponsor
CSL Behring
Responsible party
Sponsor
First posted
Feb 9, 2012
Start date
Mar 2012
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Feb 17, 2021
Last update
Feb 17, 2021

Study contacts

Javier San Martin, MD FRCP
study director · Alder Biopharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clazakizumab

Start the discussion